Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402937 | 1.00 | BLM (0.51) | BLMPOLBHCAR2KMT2AMEN1 | |
| SCHEMBL12655903 | 1.00 | BLM (0.51) | BLMPOLBHCAR2KMT2AMEN1 | |
| SCHEMBL12655475 | 0.94 | BLM (0.49) | BLMPOLBHCAR2KMT2AMEN1 | |
| SCHEMBL19147277 | 0.94 | BLM (0.49) | BLMPOLBHCAR2KMT2AMEN1 | |
| SCHEMBL16093641 | 0.94 | POLB (0.47) | BLMPOLBKMT2AMEN1TSHR | |
| SCHEMBL26972369 | 0.94 | POLB (0.47) | BLMPOLBKMT2AMEN1TSHR | |
| SCHEMBL402936 | 0.94 | POLB (0.47) | BLMPOLBKMT2AMEN1TSHR | |
| SCHEMBL12655666 | 0.92 | BLM (0.49) | BLMPOLBHCAR2KMT2AMEN1 | |
| SCHEMBL19146011 | 0.89 | HCAR2 (0.49) | BLMPOLBHCAR2KMT2AMEN1 | |
| SCHEMBL22563031 | 0.89 | HCAR2 (0.49) | BLMPOLBHCAR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912831-B2 | Hydroxyethylpyrrolidone ethacrylate/glycidyl ethacrylate copolymers | ISP INVESTMENTS LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-11859029-B2 | Methods of synthesis of homopolymers and non-homopolymers comprising repeating units derived from monomers comprising lactam and acryloyl moieties in an aqueous medium | ISP INVESTMENTS LLC (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4230264-A2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2023-08-23 | — | — | EP | disclosed |
| EP-3366668-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2023-06-21 | — | — | EP | disclosed |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-06-20 | — | — | US | disclosed |
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-08-10 | — | — | US | disclosed |
| EP-3253377-B1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-05-12 | — | — | EP | disclosed |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-11-12 | — | — | US | disclosed |
| US-10596140-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-04-06 | — | — | US | disclosed |
| US-9512325-B2 | Compositions comprising a reactive monomer and uses thereof | ISP INVESTMENTS LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512325-B2 | Compositions comprising a reactive monomer and uses thereof | ISP INVESTMENTS LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160228376-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | MORGAN STANLEY SENIOR FUNDING, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-2501728-B1 | ALKYL LACTAM ESTER POLYMERS, AND USES THEREOF | ISP INVESTMENTS INC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130150481-A1 | COMPOSITIONS COMPRISING A REACTIVE MONOMER AND USES THEREOF | HERCULES LLC | 2013-06-13 | — | — | US | disclosed |
| US-20130150481-A1 | COMPOSITIONS COMPRISING A REACTIVE MONOMER AND USES THEREOF | HERCULES LLC | 2013-06-13 | — | — | US | disclosed |
| US-8101701-B2 | having a hydrophilic group and a silicon-containing alkyl group within molecule; lenses with high oxygen permeability independent from the water content may be obtained, wherein the fumaric acid derivatives is superior in compatibility with the hydrophilic monomer used in combination | MENICON NECT CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| WO-2011063208-A1 | ALKYL LACTAM ESTER POLYMERS, AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | MENICON NECT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | BLM 2570/4885POLB 1774/4885HCAR2 613/4885 |
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | FAH, FH, AQP4 | BLM 634/4885POLB 2193/4885HCAR2 83/4885 |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | BLM 2570/4885POLB 1774/4885HCAR2 613/4885 |
| US-10596140-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | BLM 2570/4885POLB 1774/4885HCAR2 613/4885 |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | BLM 2570/4885POLB 1774/4885HCAR2 613/4885 |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | BLM 2570/4885POLB 1774/4885HCAR2 613/4885 |
| US-11912831-B2 | Hydroxyethylpyrrolidone ethacrylate/glycidyl ethacrylate copolymers | MMAB, PCNA, HMBS | BLM 1408/4885POLB 682/4885HCAR2 332/4885 |
| US-20160228376-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | DHFR, FPGS, G6PD | BLM 3677/4885POLB 3359/4885HCAR2 494/4885 |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | BLM 2570/4885POLB 1774/4885HCAR2 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.